The Pharmacy Counter as Policy Failure
A woman walks into a pharmacy in suburban Dallas with a prescription for an estrogen patch she's been using for three years. The pharmacist apologizes. They're out. They don't know when more will come in. Try another location. Maybe another brand. Maybe compounding.
This is happening across the country right now. Estrogen patches — a well-established, widely prescribed hormone therapy used by millions of post-menopausal women — are increasingly difficult to find at normal retail pharmacies. The supply chain has fractured, and the fracture has a specific cause: the FDA's recent push to accelerate hormone therapy prescribing has created a demand spike that manufacturers weren't prepared for.
The agency that was supposed to make drugs safer and more accessible has managed to make drugs less accessible. Again.
I want to be precise about what's happening here, because the temptation is to make this a simple story about government incompetence. It's more specific than that. It's a story about what happens when a regulatory agency operates without meaningful price signals and without the feedback loops that markets provide.
How Regulators Create Shortages
The pharmaceutical supply chain is not a simple system. Manufacturing estrogen patches requires specialized facilities, specific raw materials, and production planning that operates on timelines of months to years. When the FDA signals — through guidance, through approval pathways, through public communications — that prescribing of a given drug class should increase substantially, manufacturers need time to respond.
But the FDA's signal came without the price information that would normally accompany increased demand in a functioning market. If demand for estrogen patches doubled in a free market, prices would rise, which would signal manufacturers to expand capacity, which would attract additional suppliers, which would eventually bring prices back down as supply recovered. The whole process might take twelve to eighteen months and be uncomfortable for consumers in the interim — but it would resolve.
Drug markets don't work that way. Medicare, Medicaid, and private insurance negotiations suppress price signals. Manufacturers make production decisions based on contract prices negotiated years in advance. When demand spikes unexpectedly, there's no immediate price mechanism to pull additional supply into the market. There's just shortage.
The federal government created this dynamic deliberately, through decades of drug pricing policy premised on the idea that market prices for medications are inherently exploitative and must be controlled. The result is a system that is structurally incapable of responding efficiently to demand changes.
The Patients Bearing the Cost
Post-menopausal women using hormone therapy are not a monolithic group. Some are managing severe menopausal symptoms. Some are using estrogen for bone density protection. Some have a documented medical need established by years of treatment and monitoring with a physician who knows their specific situation.
None of them benefit from having their medication unavailable at their local pharmacy.
The compounding pharmacy option that gets suggested as a workaround is not a seamless substitute. Compounded medications are not FDA-regulated in the same way as commercial drugs. Their potency and purity vary. A patient who has been stable on a specific commercial formulation may respond differently to a compounded version. That's not a theoretical concern — it's a documented clinical reality.
The FDA's response to the shortage it helped create has been to encourage patients to consider alternatives and to reassure the public that supplies are being monitored. Monitoring. Not fixing. Not acknowledging the structural problem that made this predictable. Just watching.
In 2022, the baby formula shortage exposed the same dynamic: a regulatory environment that had consolidated production into a small number of manufacturers, created barriers to entry that prevented new suppliers from responding quickly, and then scrambled to manage a crisis that its own policies made inevitable. The FDA's handling of Abbott's Michigan plant closure and the resulting shortage was one of the most avoidable regulatory failures in recent memory.
What a Market Would Have Done
This is the uncomfortable conversation that healthcare policy never quite has. What would a genuinely competitive pharmaceutical market do with a hormone therapy demand spike? It would raise prices temporarily, which would attract additional manufacturers, which would increase supply, which would bring prices back toward equilibrium. The process would be messy and some consumers would pay more in the interim. But drugs would be available.
The current system has traded price stability for supply fragility. We've built a pharmaceutical distribution architecture that is exquisitely sensitive to any disruption — a regulatory decision, a manufacturing facility problem, a raw materials shortage — and cannot self-correct quickly because the price signals that would normally trigger correction have been suppressed by policy.
Women who depend on estrogen patches are paying the price of that policy choice right now. Every time they drive to a third pharmacy hoping this one has it in stock, they're experiencing what government-managed healthcare actually feels like from the inside. Not the brochure version. The real version.
The fix isn't complicated in principle. Reduce barriers to pharmaceutical manufacturing. Allow prices to function as signals. Create competitive conditions that attract multiple suppliers to each drug category rather than concentrating production in a handful of facilities. None of this will happen, because the political economy of drug pricing runs in exactly the opposite direction. But the shortage is honest about what that choice costs.
